Bessemer Group Inc. Increases Stake in Danaher Corporation $DHR

Bessemer Group Inc. increased its position in shares of Danaher Corporation (NYSE:DHR) by 6.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,388,962 shares of the conglomerate’s stock after purchasing an additional 146,725 shares during the period. Danaher makes up 0.7% of Bessemer Group Inc.’s portfolio, making the stock its 24th largest holding. Bessemer Group Inc.’s holdings in Danaher were worth $473,636,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in DHR. Sivia Capital Partners LLC grew its stake in shares of Danaher by 6.3% during the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after buying an additional 119 shares during the last quarter. Merit Financial Group LLC boosted its holdings in Danaher by 17.5% during the 2nd quarter. Merit Financial Group LLC now owns 17,099 shares of the conglomerate’s stock valued at $3,378,000 after acquiring an additional 2,544 shares during the period. BankPlus Trust Department grew its position in Danaher by 6.1% in the 2nd quarter. BankPlus Trust Department now owns 3,575 shares of the conglomerate’s stock valued at $706,000 after acquiring an additional 207 shares during the last quarter. Venturi Wealth Management LLC increased its stake in Danaher by 1,901.9% in the second quarter. Venturi Wealth Management LLC now owns 66,764 shares of the conglomerate’s stock worth $13,189,000 after purchasing an additional 63,429 shares during the period. Finally, REAP Financial Group LLC lifted its position in shares of Danaher by 197.3% during the second quarter. REAP Financial Group LLC now owns 440 shares of the conglomerate’s stock worth $87,000 after purchasing an additional 292 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of NYSE:DHR opened at $219.31 on Thursday. The firm has a 50 day moving average of $230.07 and a 200 day moving average of $214.68. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $154.91 billion, a price-to-earnings ratio of 43.51, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. The business had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The business’s revenue was up 4.6% compared to the same quarter last year. During the same period last year, the business posted $2.14 EPS. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. On average, sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Friday, December 26th were issued a $0.32 dividend. The ex-dividend date was Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s payout ratio is currently 25.40%.

Analysts Set New Price Targets

A number of research analysts have recently commented on DHR shares. Robert W. Baird set a $251.00 price target on shares of Danaher in a report on Thursday, January 29th. Wells Fargo & Company upped their target price on shares of Danaher from $230.00 to $240.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research note on Monday, December 29th. Rothschild Redb cut Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Finally, Evercore ISI reaffirmed an “outperform” rating and set a $254.00 target price on shares of Danaher in a research report on Wednesday, January 28th. Twenty research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $252.32.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Teri List sold 3,298 shares of Danaher stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares in the company, valued at approximately $4,702,593. The trade was a 13.71% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 30,248 shares of company stock valued at $6,609,663. 11.10% of the stock is currently owned by insiders.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.